Young-Do Kim | 3 Articles |
![]()
Complex regional pain syndrome (CRPS) is a chronic regional pain disorder that most frequently affects the limbs. It is characterized by hyperalgesia, allodynia, edema, motor disturbance, and vasomotor instability, and typically occurs following surgery or trauma. In type-I CRPS there is no confirmed nerve injury, while peripheral nerve injury is present in type-II CRPS. The multifactorial pathophysiological etiology of CRPS includes inflammation, autoimmune responses, abnormal cytokine production, autonomic dysfunction, altered blood flow, psychological factors, and central cortical reorganization. There are no specific laboratory diagnostic tools for CRPS, and so it is diagnosed clinically. The Budapest criteria are currently the most-accepted diagnostic criteria.
Citations Citations to this article as recorded by
A 80-year-old man was admitted due to painful paresthesia and weakness on four extremities for three months. We diagnosed chronic progressive sensorimotor polyneuropathy of unknown cause and empirically treated with oral steroid. Six-weeks later, pruritic and erythematous papules and plaques were observed on his forearms and feet, the pathologic findings by skin biopsy were compatible with Kaposi's sarcoma. We suggest that progressive sensorimotor polyneuropathy of the patient could be attributed to Kaposi's sarcoma within the context of paraneoplastic process.
Background
Recently, polyneuropathy has been been described in higher proportions for patients with Parkinson’s disease (PD) than in normal population. This finding was hypothesized to be related to the elevation of plasma homocysteine, following the management of PD with levodopa. We conducted this study to clarify the clinical value of elevated plasma homocysteine in PD patients for their relation to polyneuropathy. Methods A total of 37 PD patients without neuropathy (PD control) and 41 PD patients with polyneuropathy (PDP), who were recruited for this study, were compared with age and sex matched 48 healthy controls. All PD patients performed electrophysiological tests, including nerve conduction study, to diagnose polyneuropathy. Plasma homocysteine levels were measured in all subjects and compared between each groups. Results The homocysteine of PDP showed higher homocysteine level than those of PD control and healthy controls. However, there was no significant difference in homocysteine levels between PD control and healthy controls. In each group of PD control and PDP, there were no intercorrelations between daily levodopa dose, duration of PD symptoms and PD treatment or motor severity with homocysteine levels. Conclusions We could cautiously assume that plasma homocysteine level may be related with the involvement of peripheral nerve of PD patients in this study. The pathophysiologic role of homocysteine and the relationship between plasma homocysteine level and levodopa in PDP need to be confirmed.
|